课题基金 / 基金详情

Controlled Photochemical Release of Nitric Oxide for Biomedical Applications

Controlled Photochemical Release of Nitric Oxide for Biomedical Applications
用于生物医学应用的一氧化氮的受控光化学释放
批准号:
10590662
负责人:
STEVEN P. SCHWENDEMAN
金额:
$46.36万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-06-15 至 2025-02-28
关键词:
Acute Respiratory Distress SyndromeAdhesivesAffectAirAnimal TestingAnimalsAntiviral AgentsApicalBacteriaBiological AssayBloodBlood capillariesCell Culture TechniquesCell surfaceCellsChronicChronic Obstructive Pulmonary DiseaseClinicalCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDevicesDiseaseDissociationDoseElectron MicroscopyElectronicsEpithelial CellsExposure toFeedbackFilmFree RadicalsFrequenciesFundingGasesGenerationsGrantHistologyHomeHospitalsHumanIL8 geneIndividualInfectionInflammatoryIntensive CareIschemic Brain InjuryKnockout MiceLactate DehydrogenaseLightLightingLinkLungLung TransplantationLung infectionsMalariaMedicalMedicineMembraneMethemoglobinMethodsMicrobial BiofilmsModelingMonitorMorphologyMusMutationNeonatologyNitric OxideNitric Oxide DonorsNitrogen DioxideOrphan DrugsOutcomeOutputParticle SizePatientsPerformancePhasePneumoniaPolymersPopulationPorosityPrognosisPropertyPseudomonas aeruginosaPseudomonas aeruginosa infectionPulmonary HypertensionPulmonary TuberculosisReactionRegimenResearchResidual stateRespiratory Tract InfectionsRiskS phaseS-NitrosothiolsSignal TransductionSinusSinusitisSolidSputumStreamStrokeSurfaceSystemTechnologyTestingTherapeutic UsesTobramycinToxic effectVasodilator AgentsX ray diffraction analysisairway epitheliumantimicrobialantimicrobial drugcell preparationchronic rhinosinusitiscontrolled releasecostcrystallinitycystic fibrosis airway epitheliacystic fibrosis patientscytotoxichigh riskin vitro testingin-home careinfection riskinhaled nitric oxidelight intensitylight microscopylung failurenatural antimicrobialnovel strategiesparticleportabilitypressurepreventprototypescale upsensorsolid state

项目摘要

项目成果

STEVEN P. SCHWENDEMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT: Therapeutic use of gas phase nitric oxide (NO) has several important applications in medicine. In addition to its well-known vasodilator action, NO is a potent and endogenous antimicrobial agent normally present at moderate levels (200-1000 ppbv) in the airways/sinuses of healthy individuals, which helps preventing chronic upper airway and lung infections. Since its first medical application >20 years ago, inhaled nitric oxide (iNO) has become a mainstay of intensive care for lung failure patients and it is essential in neonatology, lung transplantation, and pulmonary hypertension. It is also used in pneumonia, acute respiratory distress syndrome (ARDS), and potentially to treat of pulmonary tuberculosis and malaria. With the widespread hospital use of iNO there is a great potential for use of iNO also in the home for treating chronic pulmonary infections related to chronic obstructive pulmonary disease (COPD, ca. 11.5 million cases in US) and chronic rhino sinusitis (CRS, ca. 31 million cases in US). Further, while cases of cystic fibrosis (CF) is less common (ca. 30,000 cases), CF patients possess a genetic defect that greatly reduces NO levels liberated by airway epithelial cells, resulting in very high risk of infection. However, iNO therapy is presently exceedingly expensive (>$3,000 per day) owing to costly NO cylinders and the associated instability of NO in such gas tanks. Therefore, current NO delivery technology is both too expensive and non-portable for potential routine use for in-home care. Using funding from an exploratory R21 grant, our research team has developed a completely new and very attractive method for light-activated NO generation directly from solid phase S-nitrosothiols (RSNO) type NO donors. We have demonstrated that light-activated feedback-controlled release of NO can be achieved precisely from RSNO loaded polymer films combined with variable LED lighting. An amperometric NO selective sensor can provide signals for a feedback circuit to control the LED light intensity to achieve a target level of NO in the output air (or O2) stream. We have identified the main parameters affecting the efficiency of NO release from such films and for minimizing the emitted levels of toxic NO2 gas. In this R01 grant our team will further study the possibilities of scaling up the light-activated NO generation system. We will test the purity of the generated NO gas and the composition of the residual solid decomposition products in order to determine light triggered reaction mechanism of the NO release from the solid state RSNO species. We will study the antimicrobial and cytotoxic properties of the generated NO gas on bacteria infected human epithelial cells and in CFTR knockout mice. This new photochemical gas phase NO generation approach will be very attractive and much lower in cost than using current iNO delivery systems employing high pressure gas tanks. Indeed, photochemically generated NO could eventually be safely extended to in-home use for certain clinical situations (e.g., CF, COPD, CRS and ARDS) to prevent and treat chronic lung infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Controlled Photochemical Release of Nitric Oxide for Biomedical Applications
Controlled Photochemical Release of Nitric Oxide for Biomedical Applications
Controlled Photo-Release of Nitric Oxide for Antimicrobial Inhalation Therapy
Investigation of peptide-polymer interactions in PLGA microspheres
海外基金